Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.

MLA

Cochrane, Tara, et al. “Impact of Venetoclax Monotherapy on the Quality of Life of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the Phase 3b VENICE II Trial.” Leukemia & Lymphoma, vol. 63, no. 2, Feb. 2022, pp. 304–14. EBSCOhost, https://doi.org/10.1080/10428194.2021.1986217.

APA

Cochrane, T., Enrico, A., Gomez-Almaguer, D., Hadjiev, E., Lech-Maranda, E., Masszi, T., Nikitin, E., Robak, T., Weinkove, R., Wu, S.-J., Sail, K. R., Pesko, J., Pai, M., Komlosi, V., & Anderson, M. A. (2022). Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. Leukemia & Lymphoma, 63(2), 304–314. https://doi.org/10.1080/10428194.2021.1986217

Chicago

Cochrane, Tara, Alicia Enrico, David Gomez-Almaguer, Evgueniy Hadjiev, Ewa Lech-Maranda, Tamas Masszi, Eugene Nikitin, et al. 2022. “Impact of Venetoclax Monotherapy on the Quality of Life of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the Phase 3b VENICE II Trial.” Leukemia & Lymphoma 63 (2): 304–14. doi:10.1080/10428194.2021.1986217.